DISCOUNT-ZERTIFIKAT - ASTRAZENECA | Delayed Deutsche Boerse AG 07:17:23 29/05/2024 BST | ||
| 117.4 EUR | -0.34% |
|
| Current month | +1.33% | ||
| 1 month | +1.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 29/05/24 | 117.4 | -0.34% |
| 28/05/24 | 117.8 | -0.82% |
| 27/05/24 | 118.8 | +0.10% |
| 24/05/24 | 118.7 | -0.03% |
| 23/05/24 | 118.7 | +0.19% |
Delayed Quote Deutsche Boerse AG
Last update May 29, 2024 at 07:17 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SV6F8S |
| ISIN | DE000SV6F8S6 |
| Date issued | 17/05/2023 |
| Maturity | 21/06/2024 (24 Days) |
| Parity | 1 : 1 |
| Emission price | 107.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 119 € |
|---|---|
| Lowest since issue | 93.42 € |
| Spread | 0.2 € |
| Spread % | 0.17% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
170.1
USD
Spread / Average Target
+10.69%
- Stock Market
- Certificates
- Certificat
